journal article·2018-01-21Open access

Route and Type of Formulation Administered Influences the Absorption and Disposition of Vitamin B12 Levels in Serum

Luis Vitetta, Joyce Zhou, Rachel Manuel, Serena Dal Forno, Sean Hall, David Rutolo

Abstract

The administration of biological compounds that optimize health benefits is an ever-evolving therapeutic goal. Pharmaceutical and other adjunctive biological compounds have been administered via many different routes in order to produce a systemic pharmacological effect. The article summarizes the findings from an Australian comparative study in adults administered vitamin B12 through different oral delivery platforms. A total of 16 subjects (9 males, 7 females) voluntarily partook in a comparative clinical study of five different vitamin B12 formulations across a six-month period, completing 474 person-hours of cumulative contribution, that was equivalent to an n = 60 participation. A nanoparticle delivered vitamin B12 through a NanoCelle platform was observed to be significantly (p < 0.05) better absorbed than all other dose equivalent platforms (i.e., tablets, emulsions, or liposomes) from baseline to 1, 3, and 6 h of the study period. The nanoparticle platform delivered vitamin B12 demonstrated an enhanced and significant absorption profile as exemplified by rapid systemic detection (i.e., 1 h from baseline) when administered to the oro-buccal mucosa with no reports of any adverse events of toxicity. The nanoparticle formulation of methylcobalamin (1000 µg/dose in 0.3 mL volume) showed bioequivalence only with a chewable-dissolvable tablet that administered a five times higher dose of methylcobalamin (5000 µg) per tablet. This study has demonstrated that an active metabolite embedded in a functional biomaterial (NanoCelle) may constitute a drug delivery method that can better access the circulatory system.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Folate and B Vitamins Research · Vitamin C and Antioxidants Research · Growth Hormone and Insulin-like Growth Factors

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Sydney Medical School, The University of Sydney, Sydney 2006, Australia

Medlab Clinical, Sydney 2015, Australia

References (29)

Show source-provided references
1. High performance affinity chromatography and related separation methods for the analysis of biological and pharmaceutical agents10.1039/C7AN01469D ↗
2. Medicinal plants and phytochemicals with anti-obesogenic potentials: A review10.1016/j.biopha.2017.02.108 ↗
3. Sun, N.N., Wu, T.Y., and Chau, C.F. (2016). Natural dietary and herbal products in anti-obesity treatment. Molecules, 21.10.3390/molecules21101351 ↗
4. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection
5. Oral bioavailability and first-pass effects
6. Parenteral or enteral arginine supplementation safety and efficacy10.3945/jn.115.228544 ↗
7. The dynamic gastric environment and its impact on drug and formulation behaviour10.1016/j.ejps.2016.08.060 ↗
8. Challenges and future prospects for the delivery of biologics: Oral mucosal, pulmonary, and transdermal routes10.1208/s12248-017-0054-z ↗
9. Nanoparticles in medicine: Current challenges facing inorganic nanoparticle toxicity assessments and standardizations10.1016/j.nano.2015.05.005 ↗
10. Nanomedicine: An unresolved regulatory issue10.1016/j.yrtph.2006.04.009 ↗
11. Advanced drug delivery to the lymphatic system: Lipid-based nanoformulations
12. Nanotechnology based approaches for anti-diabetic drugs delivery10.1016/j.diabres.2017.11.018 ↗
13. Nutraceutics and delivery systems10.1080/10611860400003817 ↗
14. Nanotechnology safety concerns revisited10.1093/toxsci/kfm169 ↗
15. Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs10.1016/j.bbrc.2015.06.177 ↗
16. Lipid-based nanovesicles for nanomedicine10.1039/C6CS00409A ↗
17. Nanomedicine: Towards development of patient-friendly drug-delivery systems for oncological applications
18. Vitamin b12 sources and bioavailability10.3181/0703-MR-67 ↗
19. Vitamin b12 in health and disease10.3390/nu2030299 ↗
20. Vitamin b12 intramuscular injections versus oral supplements: A budget impact analysis
21. Hall, S.M., Vitetta, L., Zhou, Y., Rutolo, D.A., and Coulson, S.M. (2016). Transmucosal and Transdermal Delivery Systems. (Application No. PCT/US2016/020468), International Patent.
22. Comparison of four automated serum vitamin b12 assays10.1515/cclm-2014-0843 ↗
23. A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals10.1177/00970002042006005 ↗
24. Jankowska, M., Rutkowski, B., and Debska-Slizien, A. (2017). Vitamins and microelement bioavailability in different stages of chronic kidney disease. Nutrients, 9.10.3390/nu9030282 ↗
25. Nanotechnology and human health: Risks and benefits10.1002/jat.1609 ↗
26. Liposome triggering of innate immune responses: A perspective on benefits and adverse reactions10.1080/08982100902792855 ↗
27. The interaction of liposomes with the complement system: In vitro and in vivo assays10.1016/S0076-6879(03)73010-9 ↗
28. Activation of the human complement system by cholesterol-rich and pegylated liposomes-modulation of cholesterol-rich liposome-mediated complement activation by elevated serum ldl and hdl levels10.1080/08982100600848801 ↗
29. Liposome-mediated triggering of complement cascade10.1080/08982100802309552 ↗